ECONOMIC PROSPECT ANALYSIS

Merck & Co. Inc. (MRK)

Forward-looking competitive assessment — compiled by Gemini 3.1

Moderate Prospect

Merck's Keytruda is the best-selling drug in history ($25B+ annual sales) but faces a patent cliff in 2028 that looms large. The company is aggressively building a pipeline through acquisitions (Prometheus, Acceleron) but needs multiple blockbusters to fill the gap. Gardasil growth is strong globally but facing unexpected pressure in China.

View DCF Intrinsic Value Analysis →

Competitive Momentum

22/35

Moat Durability

22/35

Sentiment & Catalysts

19/30

🚀 Key Catalysts

Subcutaneous Keytruda formulation extending the franchise beyond patent expiry and differentiating from biosimilars
Pneumococcal vaccine (V116) becoming a multi-billion dollar franchise to partially offset Keytruda losses
ADC pipeline (from Daiichi Sankyo partnership) delivering next-generation oncology drugs that leverage Keytruda's physician relationships

⚠️ Key Risks

Keytruda patent cliff in 2028 creating a $25B+ revenue hole that no single drug can replace
Gardasil demand weakness in China raising questions about international growth assumptions
Pipeline execution risk — Merck needs 3-5 blockbuster drugs to replace Keytruda, and drug development has a 90% failure rate

Methodology

Score is based on three pillars: Competitive Momentum (0-35), Moat Durability (0-35), and Sentiment & Catalysts (0-30), totaling 0-100. Each pillar is broken into individually scored factors with transparent rationale. Data sources include FY2025 10-K filings, analyst consensus estimates, news sentiment analysis, and competitive landscape assessment. The score is forward-looking and represents economic prospect over a 2-3 year horizon.

Disclaimer: This economic prospect score is for educational purposes only. It is generated by an AI model (Gemini 3.1) based on publicly available data and may not reflect all material factors. This does not constitute investment advice. Always conduct your own due diligence.